4-(Piperidin-4-yl)indolin-2-one → [2,4-Dimethyl-5-(2-oxo-4-piperidin-4-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl]-acetic Acid
Reaction equation
[NH:1]1[CH2:6][CH2:5][CH:4]([C:7]2[CH:15]=[CH:14][CH:13]=[C:12]3[C:8]=2[CH2:9][C:10](=[O:16])[NH:11]3)[CH2:3][CH2:2]1.[CH:17]([C:19]1[NH:23][C:22]([CH3:24])=[C:21]([CH2:25][C:26]([OH:28])=[O:27])[C:20]=1[CH3:29])=O>>[CH3:24][C:22]1[NH:23][C:19]([CH:17]=[C:9]2[C:8]3[C:12](=[CH:13][CH:14]=[CH:15][C:7]=3[CH:4]3[CH2:3][CH2:2][NH:1][CH2:6][CH2:5]3)[NH:11][C:10]2=[O:16])=[C:20]([CH3:29])[C:21]=1[CH2:25][C:26]([OH:28])=[O:27]Participants
3
Procedure
4-Piperidin-4-yl-1,3-dihydroindol-2-one (45 mg, 0.2 mmol) was condensed with (5-formyl-2,4-dimethyl-1H-pyrrol-3-yl)-acetic acid (40 mg, 0.23 mmol) to give the title compound.
Sources & evidence
- ORD record
- ord-256b63482f7e4b178f64412a33aeee6e
- Source dataset
- uspto-grants-2003_10
- Patent number
- US06635640B2
Reaction notes
Loading…